The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Nanoparticle micellar formulation of paclitaxel in combination with carboplatin for women with recurrent platinum sensitive ovarian cancer (OAS07-OVA): Overall survival results of a phase 3 randomized trial.
 
Nina Heldring
Employment - Oasmia Pharmaceutical AB
 
Helena Bjermo
Employment - Oasmia Pharmaceutical AB
 
Arija Brize
No Relationships to Disclose
 
Alla Sergeevua Lisyanskaya
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Tesaro (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche